The recent Supreme Court decision in the Loper Bright case has resulted in the elimination of Chevron deference, a legal doctrine that allowed federal agencies to interpret ambiguous statutes. This change is expected to impact various regulatory areas, including employee benefit plans, ERISA regulatory actions, and the authority of the Federal Energy Regulatory Commission (FERC). The Food and Drug Administration (FDA) has expressed concerns that without Chevron deference, agency determinations will be subject to increased judicial review, potentially leading to courts second-guessing agency decisions. While some argue that the removal of Chevron deference will not significantly affect AI regulation at the federal level, it remains to be seen how this shift will influence other regulatory practices.